Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Acaroid Immunotherapy in House Dust Mite Allergy
NCT00540631Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Oct 2007
- Primary completion
- Aug 2010
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 3 trial of Acaroid in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), allergic asthma, sponsored by Allergopharma. Started Oct 2007; status: completed.
02
Drugs
Acaroid
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on NCT00540631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00540631.